Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sexual dimorphism in the association of circulating TAM receptors-ligands with MASLD-related fibrosis.

JHEP reports : innovation in hepatology·2026
Same author

Erratum to 'Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis' [J Hepatol 83 (2025) 239-257].

Journal of hepatology·2026
Same author

Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis.

Cell·2026
Same author

Cannabinoid receptor 2 activating antibodies: A promising therapeutic strategy for macrophage-driven fibro-inflammatory diseases.

Molecular pharmacology·2026
Same author

Scar-associated endothelial-stellate cellular crosstalk drives fibrosis resolution in MASH.

Cell reports·2026
Same author

Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis.

Science translational medicine·2026
Same journal

Regional organization of nutrient absorption across the small intestine.

Nature reviews. Gastroenterology & hepatology·2026
Same journal

Engineering immune cell therapies for inflammatory bowel disease: from stem cells to CAR T cells.

Nature reviews. Gastroenterology & hepatology·2026
Same journal

Actin cytoskeletal dynamics in hepatic myofibroblasts and fibrosis.

Nature reviews. Gastroenterology & hepatology·2026
Same journal

Synthetic data generation: challenges and perspectives for gastrointestinal medicine.

Nature reviews. Gastroenterology & hepatology·2026
Same journal

Steatotic liver disease in Latin America: current views and perspectives.

Nature reviews. Gastroenterology & hepatology·2026
Same journal

Positive results for daraxonrasib for previously treated metastatic pancreatic cancer.

Nature reviews. Gastroenterology & hepatology·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis
06:46

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

Published on: February 25, 2022

Evolving challenges in hepatic fibrosis.

Scott L Friedman1

  • 1Mount Sinai School of Medicine, Division of Liver Diseases, New York, NY 10029, USA. scott.friedman@mssm.edu

Nature Reviews. Gastroenterology & Hepatology
|June 30, 2010
PubMed
Summary
This summary is machine-generated.

Understanding liver fibrosis mechanisms, including hepatic stellate cell (HSC) activation and new signaling pathways, is crucial. Research highlights challenges in translating experimental advances into effective diagnostics and therapies for chronic liver disease.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Experiment Videos

Last Updated: Jun 11, 2026

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis
06:46

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

Published on: February 25, 2022

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Area of Science:

  • Hepatology and Gastroenterology
  • Cellular and Molecular Biology

Background:

  • Hepatic fibrosis involves complex cellular and molecular mechanisms.
  • Hepatic stellate cell (HSC) activation is a central event in liver fibrosis progression.

Purpose of the Study:

  • To provide a comprehensive overview of current knowledge on hepatic fibrosis mechanisms.
  • To identify key challenges in translating research findings into clinical applications for liver disease.

Main Methods:

  • Review and synthesis of recent research on hepatic fibrosis.
  • Analysis of cellular sources, signaling pathways, and regulatory mechanisms involved in fibrogenesis.

Main Results:

  • Identified novel cellular sources of extracellular matrix beyond HSCs.
  • Uncovered roles for various signaling pathways (chemokine, adipokine, neuroendocrine, angiogenic, NADPH oxidase) in fibrosis.
  • Recognized the contribution of extracellular matrix stiffness, innate immunity, and gene regulation complexity.
  • Highlighted the roles of apoptosis and senescence in fibrosis resolution.

Conclusions:

  • Despite significant research progress, a gap exists between experimental findings and clinical translation for liver fibrosis.
  • Overcoming translational challenges is essential for developing new diagnostics and therapies for chronic liver disease.